Hepatic steatosis associated with exposure to elvitegravir and raltegravir.

Moderate-to-severe hepatic steatosis in people living with HIV without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir. Prospective trials are required to establish a causal association.